Choriogonadotropin alpha Other names: hCG Human chorionic gonadotropin

Therapeutic indications

Choriogonadotropin alpha is indicated for:

Follicular maturation and luteinisation

Population group: women, only adults (18 - 65 years old)

Choriogonadotropin alpha is indicated in the treatment of adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Choriogonadotropin alpha is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anovulation, oligo-ovulation

Population group: women, only adults (18 - 65 years old)

Choriogonadotropin alpha is indicated in the treatment of anovulatory or oligo-ovulatory adult women: Choriogonadotropin alpha is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory women after stimulation of follicular growth.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Choriogonadotropin alpha is contraindicated in the following cases:

Tumours of the hypothalamus or pituitary gland

at least one of
Tumor of hypothalamus
Neoplasm of pituitary gland

Ovarian enlargement, ovarian cyst

at least one of
Ovarian enlargement
Ovarian cyst and additionally not Polycystic ovary syndrome

Gynaecological haemorrhages of unknown aetiology

at least one of
Observations of vaginal bleeding
Abnormal uterine bleeding unrelated to menstrual cycle

Ovarian carcinoma, uterine carcinoma, mammary carcinoma

at least one of
Primary malignant neoplasm of ovary
Malignant neoplasm of uterus
Malignant tumor of breast

Extrauterine pregnancy in the previous 3 months

Ectopic pregnancy

Active thromboembolic disorders

Thromboembolic disorder

Primary ovarian failure

Primary ovarian failure

Malformations of sexual organs incompatible with pregnancy

Congenital anomaly of female genital system

Fibroid tumours of the uterus incompatible with pregnancy

Uterine leiomyoma

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL) 2020: OVIDREL Solution for injection
Summary of Product Characteristics (SPC) 2019: OVITRELLE Solution for injection in pre-filled syringe
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈